LungLife AI, INC - Block listing Interim Review

LungLife AI

15/05/2025 07:00

RNS Number : 7171I

LungLife AI, INC

15 May 2025

 

15 May 2025

 

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Block Admission Six Monthly Return

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block admission pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 

Name of Company:
LungLife AI, Inc.
Name of scheme:
1. 2010 Stock Incentive Plan
2. 2020 Stock Incentive Plan
3. 2021 Omnibus Long-Term Incentive Plan
Number and class of securities originally admitted:
1,356,139 common shares of US $0.0001 each
Date of admission:
15 November 2021
Period of return:
From:
15 November 2024
To:
15 May 2025
Balance of unallotted securities under scheme(s) from previous return:
1. 475,583
2. 201,374
3. 673,990
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
1. NIL
2. NIL
3. NIL
Less: Number of securities issued/allotted under scheme(s) during period:
1. NIL
2. NIL
3. NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period :
1. 475,583
2. 201,374
3. 673,990
Total number of securities in issue at the end of the period
30,658,603

 

Name of contact:
David Anderson, Chief Financial Officer
Telephone number of contact:
+44 (0)20 7933 8780

 

 

For further information please contact:

 

LungLife AI, Inc.
www.lunglifeai.com
Paul Pagano, CEO
via investors@lunglifeai.com
David Anderson, CFO
Allenby Capital Limited
Nominated Adviser and Joint Broker
Alex Brearley / Lauren Wright - Corporate Finance
Matt Butlin / Guy McDougall - Equity Sales & Corporate Broking
Tel: +44 (0)20 3328 5656
info@allenbycapital.com
Goodbody (Joint Broker)
Tel: +44 (0) 20 3841 6202
Tom Nicholson / Cameron Duncan


 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com.

 

Our Purpose is to be a driving force in the early detection to lung cancer. And our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BLRFLFFREVISLIE